Skip to main content

Parkinson's Disease clinical trials at UC Davis
4 research studies open to eligible people

  • A Study of LY3154207 in Participants With Parkinson's Disease Dementia

    open to eligible people ages 40-85

    A randomized placebo-controlled trial to evaluate the safety and efficacy of three doses of study drug LY3154207 treated for 12 weeks in participants with mild-to-moderate dementia associated with LBD (PDD or DLB).

    Sacramento, California and other locations

  • An Extension Study of Experimental AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed Study IN 11 004

    open to eligible people ages 30-100

    The purpose of this study is to allow evaluation of long-term clinical effect and safety outcome of treatment with AP-CD/LD, as well as to allow patients to benefit from extended treatment duration with AP-CD/LD after they have successfully completed the Phase 3 core study IN 11 004 ('core study', a phase III, multicenter, randomized, double-blind, double-dummy, active-controlled Phase 3 study to assess the safety and efficacy of AP CD/LD versus IR CD/LD in fluctuating PD patients).

    Reseda, California and other locations

  • Experimental drug Nilotinib in Parkinson's Disease

    open to eligible people ages 40-79

    This study will assess the safety and tolerability of daily oral administration of nilotinib (150-300mg once daily) in Parkinson's Disease.

    Sacramento, California and other locations

  • Low Frequency Deep Brain Stimulation of cognitive performance in Parkinson's Disease

    “Research evaluating memory and thinking ability”

    open to eligible people ages 18 years and up

    Prospective trial of low frequency deep brain stimulation of the ventral subthalamic nucleus to improve cognitive performance in patients with advanced Parkinson's disease. All study participants have undergone DBS implantation surgery as part of their routine care for motor manifestations of Parkinson's disease. In this study, a temporary low frequency period of stimulation will be applied to determine its effects on cognition.

    Sacramento, California

Last updated: